-
AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine
Time of Update: 2021-03-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
-
Five new drugs are planned to be breakthrough therapies from Junshi, Microchip, Novo Nordisk...
Time of Update: 2021-03-27
include:Junshi Biologics' PD-1 Teriprizumab is used in the first-line treatment of mucosal melanoma;Novo Nordisk's long-acting GLP-1 inhibitor Semaglutide (Semaglutide) is used in the treatment of NASH;The first class of Microchip's new drug Cioroni is used in the treatment of ovarian cancer;Yuheng Bio/WuXi Biologics PD-1 monoclonal antibody Sepalizumab (GLS-010) is used in the treatment of cervical cancer;Shanghai Ruixing's oxynidone capsule is used for chronic hepatitis B fibrosis.
-
A pharmaceutical company was warned for failing to comply with GMP during the inspection process
Time of Update: 2021-03-27
Violation of "Pharmaceutical Production Quality Management Regulations"The on-site inspection of Fujian Minghua Pharmaceutical Co.
-
The new requirements of the Health Commission affect a large number of secondary hospitals!
Time of Update: 2021-03-27
The "Task" clarified that, in order to improve the mental health service capabilities of medical institutions, 100% psychiatric hospitals in the pilot area have set up mental outpatient clinics, and 40% of general hospitals above the second level open mental (psychological) outpatient clinics.
-
Eli Lilly's basal insulin BIF has a hypoglycemic effect comparable to Novo Nordisk insulin
Time of Update: 2021-03-27
CompilenewbornAccording to a phase 2 clinical trial (NCT03736785), a new once-a-week basal insulin injection has similar efficacy and safety compared with once-a-day basal insulin, and has a lower incidence of hypoglycemia.
-
Where is the next leap in CAR-T therapy? Cinda Bio and other Chinese companies explore new directions
Time of Update: 2021-03-27
According to the official website of Reindeer Medical, for patients with relapsed/refractory multiple myeloma, high-dose BCMA targeted CAR-T cell therapy may provide better remission, but the adverse events are more serious.
-
The 20 best-performing new drugs in the market in 2020
Time of Update: 2021-03-27
It was first approved for marketing in the United States in December 2019, with sales revenue of US$200 million in the first year.
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-03-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-03-27
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
New oral TYK2 inhibitor! Nuocheng Jianhua Class 1 New Drug Clinical Application Accepted
Time of Update: 2021-03-27
SourceGuanlan PharmaceuticalOn February 26, Nuocheng Jianhua announced that its new drug clinical trial application for its new Tyrosine Kinase 2 (TYK2) inhibitor ICP-332 has been accepted by the China National Medical Products Administration (NMPA).
-
New news about essential medicines or increase in the proportion of essential medicines used
Time of Update: 2021-03-27
Medical Network News on March 23 Up-regulation ratio Recently, a circulating document shows that Jiangxi Province has recently adjusted the requirements for the proportion of essential medicines in public medical institutions.
-
Chengdu Better Pharmaceutical's Ampicillin Sodium for Injection has been successfully evaluated
Time of Update: 2021-03-27
On March 22, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's Ampicillin Sodium for injection successfully passed the evaluation, and it was the first in China; in addition, the company recently imitated the 4 types of dabigatran etexilate capsules.
-
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
Time of Update: 2021-03-27
As of July 2018, the data detection committee of the IMvigor130 study found that newly-treated locally advanced or metastatic urothelial cancer patients who were not suitable for cisplatin chemotherapy received Tecentriq single-agent first-line treatment, and patients with low PD-L1 expression survived As a result, the FDA has restricted Tecentriq's first-line treatment of bladder cancer as a restriction on the positive expression of PD-L1.
-
What is the production capacity of China's antibody drugs? Can the situation of key equipment and materials be broken by import?
Time of Update: 2021-03-27
In recent years, China's antibody drug commercialization production capacity has made considerable progress, but the overall production capacity is insufficient, the production capacity is scattered, the process experience is lacking, the core equipment and materials have not been localized, and the production talent echelon has not yet formed.
-
BeiGene's CD3/CD19 dual-antibody new indications will be included in the priority review
Time of Update: 2021-03-27
Belinto Oumab was approved by the NMPA on December 4 last year through the priority review method for the treatment of adult relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).
-
The focus of retail pharmacy inspections is here
Time of Update: 2021-03-27
Retail pharmacies, submit a self-inspection report before the end of NovemberIn accordance with the requirements of the "Plan", the supervision of drug business links will be supervised by each city bureau over the headquarters of drug retail chain enterprises, drug and medical device network sales companies, vaccine distribution companies, and disease prevention and control institutions (the Provincial Center for Disease Control and Prevention is governed by the Hefei Municipal Bureau).
-
Novo Nordisk launches clinical trials of long-acting insulin in China once a week
Time of Update: 2021-03-27
The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.
-
Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration
Time of Update: 2021-03-27
On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
Jinling Pharmaceutical Factory first obtained the Drug Registration Approval for this product in 2002.
-
The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States
Time of Update: 2021-03-27
Recently, the company announced that its targeted anticancer drug Pepaxto (melphalan flufenamide, also known as melflufen) has been included in the National Cancer Comprehensive Network (NCCN) clinical practice for multiple myeloma guide.
-
Jiangsu Provincial Food and Drug Administration issued notice of Bristol-Myers Squibb's cancellation of drug business license
Time of Update: 2021-03-27
On March 15, the Jiangsu Provincial Food and Drug Administration issued an announcement stating that, in accordance with the "Administrative Licensing Law", "Drug Administration Law", "Drug Distribution License Management Measures" and other relevant regulations, it was approved by Bristol-Myers Squibb (China) Pharmaceutical Co.
